Qu Biologics is a biopharmaceutical company located in Vancouver, BC, Canada.
Qu Biologics is developing Site Specific Immunomodulators (SSIs), novel immunotherapies that are designed to stimulate an innate immune response to reverse the chronic inflammation underlying many conditions such as Crohn’s disease and ulcerative colitis.
Enrollment into the Crohn’s disease clinical trial has completed and we are no longer accepting new participants. Initial Week 8 and Week 16 results are now available here. We expect to have more information about our next clinical trial in Crohn’s disease involving Qu Biologics’ Site Specific Immunomodulators (SSIs) by the end of 2017. Please email firstname.lastname@example.org for more information or to be added to our mailing list.
To send us an e-mail, please fill out the form below.
We appreciate your interest and will make every effort to reply to your message as soon as possible.